Mabpharm (HKSE:02181) Accumulated Depreciation : HK$-204.02 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Mabpharm's quarterly accumulated depreciation declined from Dec. 2022 (HK$-150.38 Mil) to Jun. 2023 (HK$0.00 Mil) but then increased from Jun. 2023 (HK$0.00 Mil) to Dec. 2023 (HK$-204.02 Mil).

Mabpharm's annual accumulated depreciation increased from Dec. 2021 (HK$-112.94 Mil) to Dec. 2022 (HK$-150.38 Mil) and increased from Dec. 2022 (HK$-150.38 Mil) to Dec. 2023 (HK$-204.02 Mil).

Mabpharm Accumulated Depreciation Historical Data

The historical data trend for Mabpharm's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Accumulated Depreciation Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-46.10

-68.41

-112.94

-150.38

-204.02

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accumulated Depreciation	Get a 7-Day Free Trial								-112.94	-	-150.38	-	-204.02

Mabpharm Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Mabpharm Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Mabpharm's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines